BRPI0508594A - moduladores de canal de ìon - Google Patents

moduladores de canal de ìon

Info

Publication number
BRPI0508594A
BRPI0508594A BRPI0508594-2A BRPI0508594A BRPI0508594A BR PI0508594 A BRPI0508594 A BR PI0508594A BR PI0508594 A BRPI0508594 A BR PI0508594A BR PI0508594 A BRPI0508594 A BR PI0508594A
Authority
BR
Brazil
Prior art keywords
compounds
ion channel
channel modulators
compositions
disease
Prior art date
Application number
BRPI0508594-2A
Other languages
English (en)
Inventor
Robert Zelle
Vincent P Galullo
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0508594A publication Critical patent/BRPI0508594A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

MODULADORES DE CANAL DE ION. A invenção refere-se a compostos, composições compreendendo os compostos, e métodos de empregar os compostos e composições de compostos. Os compostos e métodos descritos aqui podem ser empregados para a modulação terapêutica da função do canal de íon, e tratamento de doença e sintomas de doença, particularmente aqueles mediados por certos alvos de subtipo de canal de cálcio.
BRPI0508594-2A 2004-03-08 2005-03-07 moduladores de canal de ìon BRPI0508594A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55139404P 2004-03-08 2004-03-08
PCT/US2005/007913 WO2005086902A2 (en) 2004-03-08 2005-03-07 Ion channel modulators

Publications (1)

Publication Number Publication Date
BRPI0508594A true BRPI0508594A (pt) 2007-08-21

Family

ID=34976226

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508594-2A BRPI0508594A (pt) 2004-03-08 2005-03-07 moduladores de canal de ìon

Country Status (8)

Country Link
US (1) US20070191448A1 (pt)
EP (1) EP1722786A2 (pt)
JP (1) JP2007527917A (pt)
CN (1) CN1938023A (pt)
AU (1) AU2005221138A1 (pt)
BR (1) BRPI0508594A (pt)
CA (1) CA2557650A1 (pt)
WO (1) WO2005086902A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2558224A1 (en) * 2004-03-08 2005-09-22 Wyeth Ion channel modulators
CN1990473B (zh) * 2005-12-30 2013-07-10 中国人民解放军军事医学科学院毒物药物研究所 三取代1h-咪唑类化合物、其制备方法、药物组合物及其制药用途
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
DK2303021T3 (en) 2008-06-16 2019-04-08 Univ Tennessee Res Found RELATIONSHIPS FOR TREATING CANCER
CN102388130B (zh) 2009-02-27 2014-08-27 细胞动力国际有限公司 多能细胞的分化
KR101939704B1 (ko) 2010-03-01 2019-01-17 지티엑스, 인코포레이티드 암 치료용 화합물
JP6250674B2 (ja) * 2012-08-16 2017-12-20 ヤンセン ファーマシューティカ エヌ．ベー． Ｎ型カルシウムチャネル遮断剤としてのピロロピラゾール
JP6262231B2 (ja) * 2012-08-16 2018-01-17 ヤンセン ファーマシューティカ エヌ．ベー． Ｎ型カルシウムチャネル遮断剤としてのシクロペンチルピラゾール
CN105163584B (zh) 2013-03-05 2019-06-04 田纳西大学研究基金会 用于治疗癌症的化合物
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
CA2921298C (en) * 2013-08-16 2021-07-27 Janssen Pharmaceutica Nv Substituted imidazoles as n-type calcium channel blockers
BR112018016360A2 (pt) 2016-02-11 2018-12-18 Bayer Cropscience Aktiengesellschaft 2-(het)arilimidazolilcarboxiamidas substituídas como pesticidas
EP3423452B1 (en) * 2016-03-01 2025-05-07 University of Maryland, Baltimore Wnt signaling pathway inhibitors for treatments of disease
EP3263567A1 (en) * 2016-07-01 2018-01-03 AiCuris Anti-infective Cures GmbH Carboxamide-substituted pyrazoles and tri(hetero)aryl-pyrazoles for use in methods of treating and / or preventing cardiovascular diseases and / or comorbidities thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19816880A1 (de) * 1998-04-17 1999-10-21 Boehringer Ingelheim Pharma Neue Diphenyl-substituierte 5-Ring-Heterocyclen, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
TWI231757B (en) * 2001-09-21 2005-05-01 Solvay Pharm Bv 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
GT200200188A (es) * 2001-09-24 2003-06-25 Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad
DE60333094D1 (de) * 2002-04-17 2010-08-05 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren
JP2005530785A (ja) * 2002-05-09 2005-10-13 サイトキネティクス・インコーポレーテッド 化合物、組成物、及び方法
CA2536253A1 (en) * 2003-08-20 2005-03-03 Vertex Pharmaceuticals Incorporated Aminofurazan compounds useful as protein kinase inhibitors
US20070281937A1 (en) * 2004-03-08 2007-12-06 Robert Zelle Ion Channel Modulators

Also Published As

Publication number Publication date
EP1722786A2 (en) 2006-11-22
AU2005221138A1 (en) 2005-09-22
CA2557650A1 (en) 2005-09-22
WO2005086902A3 (en) 2006-07-06
JP2007527917A (ja) 2007-10-04
US20070191448A1 (en) 2007-08-16
CN1938023A (zh) 2007-03-28
WO2005086902A2 (en) 2005-09-22

Similar Documents

Publication Publication Date Title
BRPI0508532A (pt) moduladores do canal de ìon
BRPI0508537A (pt) moduladores do canal de ìon
BRPI0508556A (pt) moduladores de canal iÈnico
EA201690265A3 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
EA200700225A1 (ru) Аналоги тетрапептида
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
BRPI0607897A2 (pt) compostos oxindol e sua utilização como agentes terapêuticos
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
TW200730515A (en) N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
EA200970581A1 (ru) Кристаллическое твёрдое основание разагилина
EA200900819A1 (ru) Хиназолины для ингибирования pdk1
BRPI0615097A2 (pt) agentes para previnir e tratar distúrbios que envolvem modulação dos receptores de ryr
EA201301078A1 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
EA200870497A1 (ru) Бензимидазольные модуляторы vr1
BRPI0508522A (pt) moduladores de canal de ìon
EA200602129A1 (ru) Новое применение пептидных соединений для лечения дискинезии
DOP2005000025A (es) Compuestos de heteroaril- y fenilsulfamoilo sustituidos
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
WO2005086902A3 (en) Ion channel modulators
EA200801054A1 (ru) Производные пролинамида в качестве модуляторов натриевых каналов
EA200970436A1 (ru) Соединения карбамата для лечения депрессии
EA200970376A1 (ru) Peg-илированный паратиреоидный гормон в качестве модулятора рецептора паратиреоидного гормона и его применение

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A,5A E 6A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE A 8.6 NA RPI 2099 DE 29/03/2011.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE A DESPACHO 8.11 NA RPI 2149 DE 13/03/2012.

B08J Incorrect entry in the gazette republished [chapter 8.10 patent gazette]

Free format text: REFERENTE A PUBLICACAO NA RPI 2099 DE 29/03/2011. TEXTO CORRETO: REFERENTE A 5A E 6A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO NAO CUMPRIMENTO DO DESPACHO 8.10 NA RPI 2156 DE 02/05/2012.